GSK PLC ADR
GSK: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$52.00 | Bcq | Pkjvttqb |
GSK's Drug and Vaccine Business Looks Poised for Steady Growth Following Haleon Demerger
Business Strategy and Outlook
As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion.